Peripheral endothelial and microvascular damage in liver cirrhosis: A systematic review and meta-analysis.

cardiovascular risk cirrhosis endothelial function microcirculation

Journal

Microcirculation (New York, N.Y. : 1994)
ISSN: 1549-8719
Titre abrégé: Microcirculation
Pays: United States
ID NLM: 9434935

Informations de publication

Date de publication:
07 2022
Historique:
revised: 13 04 2022
received: 18 02 2022
accepted: 25 05 2022
pubmed: 3 6 2022
medline: 29 7 2022
entrez: 2 6 2022
Statut: ppublish

Résumé

This is the first systematic review and meta-analysis of studies using any available functional method to examine differences in peripheral endothelial function between cirrhotic and non-cirrhotic individuals. Literature search involved PubMed, Web-of-Science, and Scopus databases, as well as gray literature sources. We included studies in adult subjects evaluating endothelial function with any semi-invasive or non-invasive functional method in patients with and without liver cirrhosis. From 3378 records initially retrieved, 15 studies with a total of 570 participants were included in the final quantitative meta-analysis. In six studies examining endothelial function with flow-mediated-dilatation, no differences between patients with cirrhosis and controls were evident (WMD: 1.33, 95%CI [-2.87, 5.53], I No differences in peripheral endothelial function assessed with semi-invasive or non-invasive functional methods exist between cirrhotic and non-cirrhotic subjects. The increasing co-existence of cardiovascular risk factors leading to impaired vascular reactivity in cirrhotic patients may partly explain these findings.

Identifiants

pubmed: 35652811
doi: 10.1111/micc.12773
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e12773

Informations de copyright

© 2022 John Wiley & Sons Ltd.

Références

Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383(9930):1749-1761.
Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151-171.
Scaglione S, Kliethermes S, Cao G, et al. The epidemiology of cirrhosis in the United States: a population-based study. J Clin Gastroenterol. 2015;49(8):690-696.
Global Burden of Liver Disease: A True Burden on Health Sciences and Economies!! | World Gastroenterology Organisation [Internet]. [cited 2021 Apr 26]. Available from: https://www.worldgastroenterology.org/publications/e-wgn/e-wgn-expert-point-of-view-articles-collection/global-burden-of-liver-disease-a-true-burden-on-health-sciences-and-economies
Polyzos SA, Kechagias S, Tsochatzis EA. Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. Aliment Pharmacol Ther. 2021;54(8):1013-1025.
Iwakiri Y, Groszmann RJ. Vascular endothelial dysfunction in cirrhosis. J Hepatol. 2007;46(5):927-934.
Jourde-Chiche N, Fakhouri F, Dou L, et al. Endothelium structure and function in kidney health and disease. Nat Rev Nephrol. 2019;15(2):87-108.
Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet. 1991;337(8744):776-778.
Berzigotti A, Erice E, Gilabert R, et al. Cardiovascular risk factors and systemic endothelial function in patients with cirrhosis. Am J Gastroenterol. 2013;108(1):75-82.
Davies T, Wythe S, O'Beirne J, Martin D, Gilbert-Kawai E. Review article: the role of the microcirculation in liver cirrhosis. Aliment Pharmacol Ther. 2017;46(9):825-835.
Thomson SJ, Cowan ML, Forton DM, et al. A study of muscle tissue oxygenation and peripheral microcirculatory dysfunction in cirrhosis using near infrared spectroscopy. Liver Int. 2010;30(3):463-471.
Cazzaniga M, Salerno F, Visentin S, Cirello I, Donarini C, Cugno M. Increased flow-mediated vasodilation in cirrhotic patients with ascites: relationship with renal resistive index: FMD in cirrhosis. Liver Int. 2008;28(10):1396-1401.
Theodorakopoulou MP, Schoina M, Sarafidis P. Assessment of endothelial and microvascular function in CKD: older and newer techniques, associated risk factors, and relations with outcomes. Am J Nephrol. 2020;11:1-19.
Theodorakopoulou MP, Alexandrou ME, Bakaloudi DR, et al. Endothelial dysfunction in COPD: a systematic review and meta-analysis of studies using different functional assessment methods. ERJ Open Res. 2021;7(2):00983-2020.
Ponziani FR, Funaro B, Lupascu A, et al. Minimal hepatic encephalopathy is associated with increased cerebral vascular resistance. A transcranial doppler ultrasound study. Sci Rep. 2019;9(1):15373.
Armentano RL, Arbeitman CR, Cymberknop LJ, Farro I, Viotti R, Cardelino J. Flow mediated dilation in cirrhosis: a pilot study in different stages of the disease. 2018 40th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) [Internet]. Honolulu (HI): IEEE; 2018 [cited 2020 Dec 30]. p. 4564-6. Available from: https://ieeexplore.ieee.org/document/8513192/
Hootman JM, Driban JB, Sitler MR, Harris KP, Cattano NM. Reliability and validity of three quality rating instruments for systematic reviews of observational studies. Res Synth Methods. 2011;2(2):110-118.
Herzog R, Álvarez-Pasquin MJ, Díaz C, et al. Are healthcare workers' intentions to vaccinate related to their knowledge, beliefs and attitudes? a systematic review. BMC Public Health. 2013;13:154.
Brito-Azevedo A, Perez RM, Maranhão PA, et al. Organ dysfunction in cirrhosis: a mechanism involving the microcirculation. Eur J Gastroenterol Hepatol. 2019;31(5):618-625.
Albillos A, Rossi I, Cacho G, et al. Enhanced endothelium-dependent vasodilation in patients with cirrhosis. Am J Physiol. 1995;268(3 pt 1):G459-G464.
Jiron MI, Lee SS, Cerini R, Pugliese D, Hadengue A, Lebrec D. Effects of nitroglycerin on forearm haemodynamics in patients with cirrhosis. Clin Sci (Lond). 1988;74(4):433-436.
Ryan J, Jennings G, Dudley F, Chin-Dusting J. Smooth muscle-derived nitric oxide is elevated in isolated forearm veins in human alcoholic cirrhosis. Clin Sci (Lond). 1996;91(1):23-28.
Doi J, Shiraishi K, Haida M, Matsuzaki S. Abnormality of energy metabolism in the skeletal muscle of patients with liver cirrhosis and changes under administration of glucose and branched-chain amino acids. Tokai J Exp Clin Med. 2004;29(4):191-198.
Brito-Azevedo A, de Mello Perez R, Coelho HSM, et al. Propranolol improves endothelial dysfunction in advanced cirrhosis: the “endothelial exhaustion” hypothesis. Gut. 2016;65(8):1391-1392.
Battaglia S, Angus P, Chin-Dusting JPF. Role of the endothelium on vasoactive agents in patients with liver cirrhosis. J Gastroenterol Hepatol. 2006;21(7):1189-1193.
Helmy A, Ferguson JW, Hayes PC, Newby DE, Webb DJ. Bradykinin does not contribute to peripheral vascular tone in patients with cirrhosis and ascites. J Cardiovasc Pharmacol. 2006;47(4):556-560.
Vaughan RB, Angus PW, Chin-Dusting JPF. Evidence for altered vascular responses to exogenous endothelin-1 in patients with advanced cirrhosis with restoration of the normal vasoconstrictor response following successful liver transplantation. Gut. 2003;52(10):1505-1510.
Helmy A, Newby DE, Jalan R, Hayes PC, Webb DJ. Enhanced vasodilatation to endothelin antagonism in patients with compensated cirrhosis and the role of nitric oxide. Gut. 2003;52(3):410-415.
Helmy A, Jalan R, Newby DE, Johnston NR, Hayes PC, Webb DJ. Altered peripheral vascular responses to exogenous and endogenous endothelin-1 in patients with well-compensated cirrhosis. Hepatology. 2001;33(4):826-831.
Chin-Dusting JP, Rasaratnam B, Jennings GL, Dudley FJ. Effect of fluoroquinolone on the enhanced nitric oxide-induced peripheral vasodilation seen in cirrhosis. Ann Intern Med. 1997;127(11):985-988.
Cífková R, Pit'ha J, Trunecuka P, et al. Blood pressure, endothelial function and circulating endothelin concentrations in liver transplant recipients. J Hypertens. 2001;19(8):1359-1367.
Angeloni L, Berzigotti A, Bianchi G, Ramilli S, Magalotti D, Zoli M. Systemic Endothelial Function Evaluated by Flow-Mediated Dilatation of Brachial Artery in Patients with Liver Cirrhosis. J Hepatol; 2005:64.
Marcacci M, Fiorni M, Lattanzi A, et al. 215 is flow-mediated dilatation (FMD) assessment a reliable marker of endothelial dysfunction in liver cirrhosis? J Hepatol. 2013;58:S93.
Sárközi A, Cseh D, Gerlei Z, Kollai M. Reduced neural baroreflex sensitivity is related to enhanced endothelial function in patients with end-stage liver disease. Scand J Gastroenterol. 2018;53(2):193-199.
Seino Y, Ohki K, Nakamura T, et al. Pathophysiological characteristics of cutaneous microcirculation in patients with liver cirrhosis: relationships to cardiovascular hemodynamics and plasma neurohormonal factors. Microvasc Res. 1993;46(2):206-215.
Aird WC. Phenotypic heterogeneity of the endothelium. Circ Res. 2007;100(2):158-173.
Flammer AJ, Anderson T, Celermajer DS, et al. The assessment of endothelial function: from research into clinical practice. Circulation. 2012;126(6):753-767.
Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol. 2004;15(8):1983-1992.
Bosch J, Abraldes JG, Fernández M, García-Pagán JC. Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. J Hepatol. 2010;53(3):558-567.
Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough: the paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology. 2002;35(2):478-491.
Keeling AN, Flaherty JD, Davarpanah AH, et al. Coronary multidetector computed tomographic angiography to evaluate coronary artery disease in liver transplant candidates: methods, feasibility and initial experience. J Cardiovasc Med (Hagerstown). 2011;12(7):460-468.
McAvoy NC, Kochar N, McKillop G, Newby DE, Hayes PC. Prevalence of coronary artery calcification in patients undergoing assessment for orthotopic liver transplantation. Liver Transpl. 2008;14(12):1725-1731.
Tiukinhoy-Laing SD, Rossi JS, Bayram M, et al. Cardiac hemodynamic and coronary angiographic characteristics of patients being evaluated for liver transplantation. Am J Cardiol. 2006;98(2):178-181.
Carrier P, Debette-Gratien M, Jacques J, Loustaud-Ratti V. Cirrhotic patients and older people. World J Hepatol. 2019;11(9):663-677.
Kanwal F, Tansel A, Kramer JR, Feng H, Asch SM, El-Serag HB. Trends in 30-day and 1-year mortality among patients hospitalized with cirrhosis from 2004 to 2013. Am J Gastroenterol. 2017;112(8):1287-1297.
Schmidt ML, Barritt AS, Orman ES, Hayashi PH. Decreasing mortality among patients hospitalized with cirrhosis in the United States from 2002 through 2010. Gastroenterology. 2015;148(5):967-977.e2.
Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol. 2020;18(12):2650-2666.
Papatheodoridis GV, Sypsa V, Dalekos G, et al. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. J Hepatol. 2018;68(6):1129-1136.
Fede G, Privitera G, Tomaselli T, Spadaro L, Purrello F. Cardiovascular dysfunction in patients with liver cirrhosis. Ann Gastroenterol. 2015;28(1):31-40.
European Association for the Study of the liver (EASL), European Association for the Study of diabetes (EASD), European Association for the Study of obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-1402.
Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11-20.
Adam R, Karam V, Cailliez V, et al. 2018 annual report of the European liver transplant registry (ELTR)-50-year evolution of liver transplantation. Transpl Int. 2018;31(12):1293-1317.
Khandelwal R, Dassanayake AS, Conjeevaram HS, Singh SP. Non-alcoholic fatty liver disease in diabetes: when to refer to the hepatologist? World J Diabetes. 2021;12(9):1479-1493.
Edens MA, Kuipers F, Stolk RP. Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers. Obes Rev. 2009;10(4):412-419.
Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2007;191(2):235-240.
Hamaguchi M, Kojima T, Takeda N, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol. 2007;13(10):1579-1584.
Hadi HA, Carr CS, Al SJ. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag. 2005;1(3):183-198.
Shechter M, Issachar A, Marai I, et al. Long-term association of brachial artery flow-mediated vasodilation and cardiovascular events in middle-aged subjects with no apparent heart disease. Int J Cardiol. 2009;134(1):52-58.
Anderson TJ, Charbonneau F, Title LM, et al. Microvascular function predicts cardiovascular events in primary prevention: long-term results from the firefighters and their endothelium (FATE) study. Circulation. 2011;123(2):163-169.
Higgins J, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions [Internet]. 2nd ed. John Wiley & Sons; 2019 Available from: https://training.cochrane.org/handbook/current

Auteurs

Ioanna Papagiouvanni (I)

Fourth Department of Internal Medicine, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Marieta P Theodorakopoulou (MP)

Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Pantelis A Sarafidis (PA)

Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Emmanouil Sinakos (E)

Fourth Department of Internal Medicine, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Ioannis Goulis (I)

Fourth Department of Internal Medicine, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH